Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

EIK1005-002: En klinisk forskningsstudie som evaluerer EIK1005, en Werner-helicasehemmer, som monoterapi og i kombinasjon med pembrolizumab hos deltakere med avanserte solide tumorer inkludert tumorer med høy mikrosatellitt-instabilitet (MSI-H)

29. oktober 2026 oppdatert av: Eikon Therapeutics

En multicenter, flerdelt, fase 1/2-studie av EIK1005 som monoterapi og i kombinasjon med pembrolizumab hos deltakere med avanserte solide svulster, inkludert pasienter uten tidligere behandling med sjekkpunkthemmere med mikrostatellitt-instabilitet høy (MSI-H) eller mismatch-reparasjonsdeficiente (dMMR) svulster

The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.

Studieoversikt

Detaljert beskrivelse

This Phase 1/2 study (EIK1005-002) will investigate the safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of EIK1005 as a monotherapy and in combination with pembrolizumab in participants with advanced solid tumors, including participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors.

The study will be conducted in 2 parts: Part 1 and Part 2, with Part 1 being further divided into Part 1A and Part 1B as described below:

  • Part 1A (monotherapy dose escalation): participants will receive EIK1005 only.
  • Part 1B (combination dose escalation): participants will receive EIK1005 in combination with pembrolizumab.
  • Part 2 (dose optimization): participants will be randomized 1:1 to monotherapy with EIK1005 at one of the two selected doses from Part 1A to identify the dose of EIK1005 in monotherapy for subsequent studies.

Studietype

Intervensjonell

Registrering (Antatt)

160

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • New South Wales
      • Saint Leonards, New South Wales, Australia
        • Har ikke rekruttert ennå
        • GenesisCare North Shore (Oncology)
      • Waratah, New South Wales, Australia
        • Rekruttering
        • Calvary Mater Newcastle Hospital
    • Victoria
      • Ballarat, Victoria, Australia
        • Rekruttering
        • Grampians Health
      • Camperdown, Victoria, Australia
        • Rekruttering
        • Chris O'Brien Lifehouse (Sydney Cancer Centre)
      • Frankston, Victoria, Australia
        • Rekruttering
        • Peninsula and Southeast Oncology (PASO) Medical
      • Frankston, Victoria, Australia, 3199
        • Rekruttering
        • Oncology Clinics Victoria (OCV) - Cabrini Brighton Hospital
      • Brussels, Belgia, 1020
        • Rekruttering
        • Centre Hospitalier Universitaire Brugmann - Victor Horta
      • Kuopio, Finland, 70210
        • Rekruttering
        • Kuopio University Hospital
    • California
      • Los Angeles, California, Forente stater, 90027
        • Rekruttering
        • California Research Institute (CRI)
    • Florida
      • Doral, Florida, Forente stater, 33172
        • Rekruttering
        • Omnicure Clinical Research
      • Hialeah, Florida, Forente stater, 33013
        • Rekruttering
        • Bioresearch Partner
      • Plantation, Florida, Forente stater, 33322
        • Rekruttering
        • Florida Clinical Trials Group
      • Tamarac, Florida, Forente stater, 33321
        • Rekruttering
        • Florida Clinical Trials Group - Tamarac
    • New Jersey
      • Morristown, New Jersey, Forente stater, 07960
        • Rekruttering
        • Morristown Medical Center
    • New York
      • Lake Success, New York, Forente stater, 11042
        • Rekruttering
        • START New York-Long Island
      • New York, New York, Forente stater, 10022
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center (MSKCC)
    • Texas
      • Fort Worth, Texas, Forente stater, 76104
        • Rekruttering
        • START Dallas Fort Worth
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • University of Texas MD Anderson Cancer Center
    • Rhone
      • Pierre-Bénite, Rhone, Frankrike, 69310
        • Rekruttering
        • Hospices Civils De Lyon (hcl) -Centre Hospitalier Lyon-Sud
      • Rome, Italia, 00128
        • Rekruttering
        • Campus Bio-Medico di Rome University
      • Wellington, New Zealand
        • Rekruttering
        • Health New Zealand
    • Manawatu
      • Roslyn, Manawatu, New Zealand, 4414
        • Rekruttering
        • Palmerstone North Hospital
      • Oslo, Norge, 0379
        • Rekruttering
        • Oslo University
      • Krakow, Polen, 31-864
        • Rekruttering
        • GCPMED Sp. z o.o., Centrum Medyczne iMed24
      • Lodz, Polen, 90-338
        • Rekruttering
        • Centrum Terapii Wspolczesnej J.M. Jasnorzewska Spolka Komandytowo-Akcyjna
    • West Pomeranian Voivodeship
      • Szczecin, West Pomeranian Voivodeship, Polen, 70-419
        • Rekruttering
        • One Day Med
      • Lisbon, Portugal, 1649-028
        • Rekruttering
        • Hospital de Santa Maria
      • Loures, Portugal, 2674-514
        • Rekruttering
        • Unidade Local de Saúde (ULS) Loures Odivelas
      • Porto, Portugal, 4200
        • Rekruttering
        • Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. (IPO Porto)
    • Lisbon District
      • Lisbon, Lisbon District, Portugal, 1500-650
        • Rekruttering
        • Hospital da Luz Lisboa
      • Singapore, Singapore, 119074
        • Rekruttering
        • National University Hospital (NUH)
    • Central Region
      • Singapore, Central Region, Singapore, 168583
        • Rekruttering
        • National Cancer Centre Singapore (NCCS)
      • Barcelona, Spania, 08023
        • Rekruttering
        • START - Barcelona
      • Logroño, Spania, 26006
        • Rekruttering
        • START Rioja - Hospital de San Pedro
      • Madrid, Spania, 28233
        • Rekruttering
        • NEXT Madrid HUQSM
      • Zaragoza, Spania, 50009
        • Rekruttering
        • Hospital Universitario Miguel Servet
    • Balearic Islands
      • Palma, Balearic Islands, Spania, 07120
        • Rekruttering
        • Hospital Universitari Son Espases
    • Barcelona
      • Barcelona, Barcelona, Spania, 8036
        • Rekruttering
        • Hospital Clinic Barcelona
      • Seoul, Sør -Korea, 02841
        • Rekruttering
        • Korea University Anam Hospital
      • Suwon, Sør -Korea, 16499
        • Rekruttering
        • Ajou University School of Medicine & Graduate School of Medicine
    • Busan
      • Busan, Busan, Sør -Korea, 48108
        • Rekruttering
        • Inje University-Haeundae Paik Hospital
      • Berlin, Tyskland, 13125
        • Rekruttering
        • Helios Klinikum Berlin-Buch
      • Hamburg, Tyskland, 22297
        • Rekruttering
        • Norddeutsches Studienzentrum fur Innovative Onkologie (NIO) Hamatologisch Onkologische Praxis Eppendorf (HOPE)
    • Bavaria
      • Deggendorf, Bavaria, Tyskland, 94469
        • Rekruttering
        • DONAUISAR Klinikum
      • Linz, Østerrike, 4020
        • Rekruttering
        • Ordensklinikum Linz Elisabethinen

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Key Inclusion Criteria:

  1. is ≥ 18 years of age at the time of signing the informed consent.
  2. has a life expectancy of at least 3 months.
  3. has histologically or cytologically documented advanced (unresectable and/or metastatic) solid tumor. Part 1A: recommend that participants have archival tissue not more than 3 years old. Part 1B and Part 2: participant has locally confirmed Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) tumor. Participant must have archival tumor tissue (not more than 3 years old) for retrospective confirmation of MSI-H or dMMR tumor by a central laboratory.
  4. In Part 1A, has received and then progressed after or is intolerant to at least 1 standard treatment regimen in the advanced setting. The participant does not have alternative therapeutic options per PI's medical judgement. Preference should be given to: (1) participants with MSI-H or dMMR cancers that have progressed after checkpoint inhibitor (CPI) therapy and (2) participants with microsatellite stable cells (MSS) cancers that have progressed following at least one regimen of platinum, alkylating or topoisomerase containing chemotherapy.
  5. has measurable disease at baseline according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the PI.
  6. has an Eastern Cooperative Oncology Group (ECOG) score of 0 to 1.
  7. has an adequate organ and marrow function.

Key Exclusion Criteria:

  1. has not recovered (i.e., to Grade ≤ 1 or to baseline) from prior anti-cancer therapy-induced adverse events (AEs).
  2. has received prior treatment with Werner (WRN) inhibitor.
  3. has a history of relevant drug hypersensitivity, ascertained or presumptive allergy/hypersensitivity to the active drug substance and/or formulation ingredients, history of serious allergic reactions leading to hospitalization, or any other allergic reaction in general.
  4. In Parts 1B and Part 2 Rescue: diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.
  5. has known additional malignancy that is progressing or has required active treatment within the past 3 years.
  6. has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable (ie, without evidence of progression) for at least 4 weeks as confirmed by repeat imaging performed during the study screening, are clinically stable and have not required steroid treatment for at least 14 days before the first dose of study treatment.
  7. has mean resting QTcF > 470 ms (men and women) obtained from triplicate electrocardiograms (ECGs).
  8. has active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Participants may enroll with the following conditions: Type 1 diabetes, hypothyroidism requiring hormone replacement, or skin disorders (vitiligo, psoriasis, or alopecia not requiring systemic treatment).
  9. has history of (non-infectious) pneumonitis/pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease.
  10. has active tuberculosis.
  11. has any active infections requiring systemic therapy.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Part 1A (Dose escalation, Monotherapy)

EIK1005 will be given as monotherapy in participants without alternative treatment options.

EIK1005 is a selective inhibitor of the Werner helicase.

Eksperimentell: Part 1B (Dose escalation, Combination with pembrolizumab)

EIK1005 will be given in combination with pembrolizumab to participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) solid tumors.

EIK1005 is a selective inhibitor of the Werner helicase.

Pembrolizumab is a PD-1 inhibitor.

Eksperimentell: Part 2 (Dose optimization, Monotherapy)

Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) advanced solid tumors will be randomized to receive EIK1005 monotherapy at one of the two identified doses selected from Part 1A.

EIK1005 is a selective inhibitor of the Werner helicase.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Dose-Limiting Toxicity (DLT) - Part 1
Tidsramme: 21 Days

A DLT is a protocol-defined adverse event occurring during the DLT observation period.

21 Days
Adverse Events (AEs) - Part 1 and Part 2
Tidsramme: From the time of first dose of study medication through 30 days following cessation of study treatment.

Number of participants reporting adverse events or serious adverse events.

From the time of first dose of study medication through 30 days following cessation of study treatment.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Objective Response (OR) - Part 1 and Part 2
Tidsramme: Through study completion, an average of 2 years.

OR defined as participants who have a complete response [CR] or partial response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1 as assessed by the Investigator.

Through study completion, an average of 2 years.
Duration of Response (DOR) - Part 1 and Part 2
Tidsramme: Through study completion, an average of 2 years.

DOR (defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first, in participants demonstrating CR or PR) by RECIST 1.1 as assessed by the Investigator.

Through study completion, an average of 2 years.
Disease Control (DC) - Part 1 and Part 2
Tidsramme: Through study completion, an average of 2 years.

DC defined as participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD) by RECIST 1.1 as assessed by the Investigator.

Through study completion, an average of 2 years.
Progression-free survival (PFS) - Part 2
Tidsramme: Through study completion, an average of 2 years.

PFS defined as the time from randomization to the first documented disease progression by RECIST 1.1 as assessed by the Investigator or death due to any cause, whichever occurs first.

Through study completion, an average of 2 years.
Pharmacokinetic (PK) parameters of EIK1005 - AUC0-24 (Part 1 and Part 2)
Tidsramme: Up to 1 year

AUC0-24 (Area Under the plasma Concentration versus time curve from 0 to 24 hours): Measures total drug exposure over the first 24 hours after dosing of EIK1005 as monotherapy and in combination with pembrolizumab.

Up to 1 year
Pharmacokinetic (PK) parameters of EIK1005 - AUCtau,ss (Part 1 and Part 2)
Tidsramme: Up to 1 year

AUCtau,ss [Area Under the plasma Concentration versus time curve over one dosing interval (tau) at steady state]: Reflects average drug exposure during each dosing interval once the steady state has been reached for EIK1005 as monotherapy and in combination with pembrolizumab.

Up to 1 year
Pharmacokinetic (PK) parameters of EIK1005 - Cmax (Part 1 and Part 2)
Tidsramme: Up to 1 year

Cmax (Maximum Plasma Concentration) after dose administration of EIK1005 as monotherapy and in combination with pembrolizumab.

Up to 1 year
Pharmacokinetic (PK) parameters of EIK1005 - tmax (Part 1 and Part 2)
Tidsramme: Up to 1 year

tmax (the time required for the plasma concentration of the drug to reach maximum concentration after dose administration) of EIK1005 as monotherapy and in combination with pembrolizumab.

Up to 1 year
Pharmacokinetic (PK) parameters of EIK1005 - t½ (Half-life) (Part 1 and Part 2)
Tidsramme: Up to 1 year

Half-life (the time required for the plasma concentration of the drug to decrease by 50% after the dose administration) of EIK1005 as monotherapy and in combination with pembrolizumab.

Up to 1 year

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Studieleder: Nilou Mobashery, MD, Eikon Therapeutics, Inc.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

20. januar 2026

Primær fullføring (Antatt)

1. mars 2029

Studiet fullført (Antatt)

1. mars 2029

Datoer for studieregistrering

Først innsendt

10. november 2025

Først innsendt som oppfylte QC-kriteriene

1. desember 2025

Først lagt ut (Faktiske)

3. desember 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

30. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

29. oktober 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere